Company news
Innoviva, Inc. news in 2023
Innoviva, Inc.'s news releases, calls and decks from 2023, newest first.
Positive Results Announced in Largest Pivotal Phase 3 Trial of a First-in-Class Oral Antibiotic to Treat Uncomplicated Gonorrhea
October 31, 2023
Innoviva Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
October 31, 2023
Innoviva Specialty Therapeutics Presents New Data on its Critical Care Antibiotic Therapy Portfolio at Infectious Disease Week (IDWeek) 2023
October 10, 2023
Innoviva to Participate in the Cantor Global Healthcare Conference
September 18, 2023
XACDURO®, The First and Only Antibiotic Developed to Target Acinetobacter, Now Available to Treat Hospital-Acquired Bacterial Pneumonia (HABP) and Ventilator-Associated Bacterial Pneumonia (VABP) in Adults
September 17, 2023
Innoviva Appoints Stephen Basso as Chief Financial Officer
August 24, 2023
Innoviva Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress
August 1, 2023
Armata Pharmaceuticals Announces New Financing and Leadership Transition to Accelerate Novel Bacteriophage Therapeutics
July 10, 2023
Innoviva to Participate in the Goldman Sachs Annual Global Healthcare Conference
June 5, 2023
Innoviva Specialty Therapeutics Announces FDA Approval for XACDURO® (sulbactam for injection; durlobactam for injection), Co-packaged for Intravenous Use
May 22, 2023
Results from Pivotal Phase 3 ATTACK Trial of Investigational Sulbactam-Durlobactam for Treatment of Serious Infections Caused by Acinetobacter Published in The Lancet Infectious Diseases
May 10, 2023
Innoviva Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress
May 8, 2023
Innoviva Announces Retirement of Board Chairman
April 27, 2023
Sulbactam-Durlobactam Unanimously Recommended for Approval by FDA Advisory Committee
April 16, 2023
Innoviva Announces FDA Advisory Committee Meeting to Review Sulbactam-Durlobactam (SUL-DUR), an Investigational Targeted Antibiotic
March 12, 2023
Innoviva Reports Fourth Quarter 2022 Financial Results and Highlights Recent Company Progress
February 27, 2023
Decks in 2023
- Technical Presentation (November 2023)
Technical · 7 slides · Nov 6, 2023
- Investor Presentation (May 2023)
Investor deck · 22 slides · May 24, 2023